In this sense, our data are in accordance with previous results in (i) colorectal cancer where high SAMHD1 expression level in tumors correlated to increased risk of metastases [15], (ii) in untreated classical Hodgkin lymphoma, where SAMHD1 was an independent adverse prognostic factor [52] and also in (iii) NSCLC EGFR mutated cancer patients where SAMHD1 serum levels were significantly increased when compared with normal control, upon cancer progression [16]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.